Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [
ATP Binding Cassette Transporter, Subfamily B
/ antagonists & inhibitors
ATP Binding Cassette Transporter, Subfamily G, Member 2
/ antagonists & inhibitors
Animals
Antineoplastic Agents
/ administration & dosage
Blood-Brain Barrier
/ drug effects
Brain
/ drug effects
Carbon Radioisotopes
/ metabolism
Cell Membrane Permeability
Drug Delivery Systems
Drug Therapy, Combination
Erlotinib Hydrochloride
/ administration & dosage
Female
Human Embryonic Stem Cells
/ drug effects
Humans
Macaca mulatta
Male
Mice
Neoplasm Proteins
/ antagonists & inhibitors
Quinolines
/ pharmacology
Blood–brain barrier
P-glycoprotein
brain delivery
breast cancer resistance protein
transporter inhibition
Journal
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
ISSN: 1559-7016
Titre abrégé: J Cereb Blood Flow Metab
Pays: United States
ID NLM: 8112566
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
pubmed:
22
10
2020
medline:
21
8
2021
entrez:
21
10
2020
Statut:
ppublish
Résumé
P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict at the blood-brain barrier (BBB) the brain distribution of the majority of currently known molecularly targeted anticancer drugs. To improve brain delivery of dual ABCB1/ABCG2 substrates, both ABCB1 and ABCG2 need to be inhibited simultaneously at the BBB. We examined the feasibility of simultaneous ABCB1/ABCG2 inhibition with i.v. co-infusion of erlotinib and tariquidar by studying brain distribution of the model ABCB1/ABCG2 substrate [
Identifiants
pubmed: 33081568
doi: 10.1177/0271678X20965500
pmc: PMC8221757
doi:
Substances chimiques
ABCB1 protein, human
0
ABCG2 protein, human
0
ATP Binding Cassette Transporter, Subfamily B
0
ATP Binding Cassette Transporter, Subfamily G, Member 2
0
Antineoplastic Agents
0
Carbon Radioisotopes
0
Neoplasm Proteins
0
Quinolines
0
Erlotinib Hydrochloride
DA87705X9K
tariquidar
J58862DTVD
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1634-1646Références
J Cereb Blood Flow Metab. 2015 May;35(5):743-6
pubmed: 25669913
Clin Pharmacol Ther. 2018 Jul;104(1):139-147
pubmed: 28940241
Drug Metab Dispos. 2019 Apr;47(4):393-404
pubmed: 30705084
Nat Rev Drug Discov. 2006 Mar;5(3):219-34
pubmed: 16518375
Drug Metab Dispos. 2013 Apr;41(4):754-62
pubmed: 23305710
J Nucl Med. 2018 Jun;59(6):973-979
pubmed: 29175983
Curr Pharm Des. 2011;17(26):2793-802
pubmed: 21827403
Nature. 2013 Sep 19;501(7467):373-9
pubmed: 23995685
EJNMMI Radiopharm Chem. 2018;3(1):8
pubmed: 29888317
Invest New Drugs. 2012 Apr;30(2):443-9
pubmed: 20963470
Eur J Nucl Med Mol Imaging. 2010 May;37(5):942-53
pubmed: 20016890
J Cereb Blood Flow Metab. 2012 Nov;32(11):2002-11
pubmed: 22828996
Cancer Sci. 2009 Sep;100(9):1701-7
pubmed: 19493273
Neurobiol Dis. 2010 Jan;37(1):13-25
pubmed: 19664713
J Cereb Blood Flow Metab. 2020 Apr;40(4):799-807
pubmed: 31006308
J Clin Pharmacol. 2006 Mar;46(3):282-90
pubmed: 16490804
Drug Metab Dispos. 2013 Jan;41(1):33-9
pubmed: 23014761
J Pharm Sci. 2011 Sep;100(9):3939-50
pubmed: 21254069
Clin Pharmacol Ther. 2016 Aug;100(2):131-41
pubmed: 26940368
J Nucl Med. 2018 Oct;59(10):1609-1615
pubmed: 29748235
Cancer. 2006 Sep 1;107(5):1034-41
pubmed: 16878326
J Pharmacol Exp Ther. 2010 Jun;333(3):788-96
pubmed: 20304939
Neuroimage. 2010 Jan 15;49(2):1406-15
pubmed: 19796699
Drug Resist Updat. 2015 Mar;19:1-12
pubmed: 25791797
Pharmaceutics. 2019 Nov 11;11(11):
pubmed: 31718023
EMBO Mol Med. 2019 Apr;11(4):
pubmed: 30808679
J Nucl Med. 2010 Apr;51(4):559-66
pubmed: 20237038
J Pharm Sci. 2018 Aug;107(8):2225-2235
pubmed: 29608887
Drug Deliv Transl Res. 2018 Jun;8(3):536-542
pubmed: 29294257
J Control Release. 2018 Dec 28;292:210-220
pubmed: 30415015
Nat Commun. 2018 Nov 21;9(1):4904
pubmed: 30464169
Adv Cancer Res. 2015;125:1-41
pubmed: 25640265
Animal Model Exp Med. 2018 Dec 04;1(4):314-321
pubmed: 30891581
Expert Rev Mol Med. 2011 May 13;13:e17
pubmed: 21676290
Mol Pharm. 2019 Mar 4;16(3):1282-1293
pubmed: 30694684
Mol Imaging. 2003 Jul;2(3):131-7
pubmed: 14649056
J Nucl Med. 2017 Jan;58(1):117-122
pubmed: 27493269
J Cereb Blood Flow Metab. 1990 Sep;10(5):740-7
pubmed: 2384545
Pharm Res. 2008 Jun;25(6):1469-83
pubmed: 18219561
J Nucl Med. 2019 Apr;60(4):486-491
pubmed: 30237210
Mol Pharm. 2015 Sep 8;12(9):3214-25
pubmed: 26202880
Neuro Oncol. 2018 Feb 19;20(3):307-312
pubmed: 29016919
J Nucl Med. 2015 Dec;56(12):1930-6
pubmed: 26359257
Clin Lung Cancer. 2017 Jul;18(4):354-363
pubmed: 28245967
Clin Pharmacol Ther. 2012 Feb;91(2):227-33
pubmed: 22166851
J Nucl Med. 2015 Jan;56(1):82-7
pubmed: 25500831
Drug Discov Today. 2019 May;24(5):1067-1073
pubmed: 30710641
Drug Metab Dispos. 2015 Apr;43(4):490-509
pubmed: 25587128
Nat Rev Cancer. 2018 Jul;18(7):452-464
pubmed: 29643473
Sci Rep. 2019 Mar 21;9(1):5012
pubmed: 30899038